Shanghai Anset Biotechnology

Anset Biotech is a clinical-stage biotechnology company based in Shanghai, China, specializing in the development of innovative cell and gene therapies. The company focuses on next-generation CAR-T cell therapies designed to address limitations in current treatments for hematologic malignancies and autoimmune disorders. Their proprietary technology platform aims to improve the persistence and efficacy of engineered T-cells while reducing toxicity. Anset Biotech is currently advancing several candidates through early-stage clinical trials, targeting high-unmet-need indications such as refractory B-cell lymphoma and systemic lupus erythematosus.